PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.

Date publication

novembre 2020

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Pr AUBIN François , Mme LAHEURTE Caroline , Dr NARDIN Charlée

Tous les auteurs :
Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33188038

Résumé

Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated.

Mots clés

CD8-Positive T-Lymphocytes, costimulatory and inhibitory T-Cell receptors, immunotherapy, melanoma, programmed cell death 1 receptor

Référence

J Immunother Cancer. 2020 Nov;8(2):